Printer Friendly

ReddyPort Inc reports US FDA's clearance for ReddyPort NIV Access Elbow in aid of patients undergoing noninvasive ventilation therapy.

M2 EQUITYBITES-March 16, 2018-ReddyPort Inc reports US FDA's clearance for ReddyPort NIV Access Elbow in aid of patients undergoing noninvasive ventilation therapy

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Ventilation products company ReddyPort Inc stated on Thursday that it has been awarded the regulatory clearance from the US Food and Drug Administration (FDA) for the first multiple-use access elbow that attaches to noninvasive ventilation (NIV) masks, the ReddyPort NIV Access Elbow.

According to the company, it has a platform of unique NIV Products designed to work with the ReddyPort elbow. The ReddyPort Elbow, along with ReddyPort NIV products, provides a variety of therapies to be delivered to patients undergoing NIV therapy, without disrupting therapeutic pressure.

Additionally, the company's NIV Products for use with the ReddyPort Elbow are subject to future regulatory review.

The ReddyPort Oral Care Kit allows patients to receive routine oral care while maintaining pressure in the mask; The ReddyPort Microphone Kit amplifies a patient's voice during NIV; The ReddyPort Nebulizer is a fully enclosed vibrating mesh nebulizer designed to go through the ReddyPort Elbow; And The ReddyPort Capnography Adapter allows for accurate CO2 sampling through the mask during NIV therapy, added the company.

In conjunction with the US FDA clearance, the company will now present its ReddyPort NIV Access Elbow and NIV products at the upcoming American Association of Critical-Care Nurses Critical Care Exposition from 20-24 May 2018 in Boston.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 16, 2018
Words:245
Previous Article:Philips wins US FDA 510(k) clearance to market its premium digital radiography, the ProxiDiagnost N90.
Next Article:Three Neuberger Berman closed-end intermediate municipal funds declare distributions for March 2018.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters